Biallelic markers of d-amino acid oxidase and uses thereof
The invention concerns the human DAO gene, polynucleotides, and biallelic markers. The invention also concerns the association established between schizophrenia and the biallelic markers. The invention provides means to determine the predisposition of individuals to schizophrenia or related CNS disorder, as well as means for the disease diagnosis and prognosis.
1 . A method of determining a genotype of an individual comprising the steps of:
a) obtaining a biological sample containing a polynucleotide from said individual; and
b) determining the identity of a nucleotide at a biallelic marker of the DAO gene of SEQ ID NO:1 or 4, in said polynucleotide, wherein said nucleotide at said biallelic marker is selected from the group consisting of: nucleotide G at biallelic marker 27-81-180, nucleotide A at biallelic marker 27-81-180, nucleotide T at biallelic marker 27-29-224, nucleotide G at biallelic marker 27-29-224, nucleotide C at biallelic marker 27-2-106, nucleotide A at biallelic marker 27-2-106, nucleotide C at biallelic marker 27-30-249, nucleotide T at biallelic marker 27-30-249, nucleotide A at biallelic marker 27-1-61, nucleotide G at biallelic marker 27-1-61;
and wherein said nucleotide determines said genotype of said individual.
2 . A method of determining whether an association between an allele of a biallelic marker of the DAO gene of SEQ ID NO:1 or 4 and schizophrenia exists, wherein said allele is defined by the identity of a nucleotide at said biallelic marker, and wherein said nucleotide and said biallelic marker is selected from the group consisting of: nucleotide G at biallelic marker 27-81-180, nucleotide A at biallelic marker 27-81-180, nucleotide T at biallelic marker 27-29-224, nucleotide G at biallelic marker 27-29-224, nucleotide C at biallelic marker 27-2-106, nucleotide A at biallelic marker 27-2-106, nucleotide C at biallelic marker 27-30-249, nucleotide T at biallelic marker 27-30-249, nucleotide A at biallelic marker 27-1-61, nucleotide G at biallelic marker 27-1-61, comprising the steps of:
a) determining a schizophrenia-positive frequency of said allele in a schizophrenia-positive population of at least 50 individuals;
b) determining a schizophrenia-negative frequency of said allele in a schizophrenia-negative population of at least 50 individuals; and
c) using said schizophrenia-positive frequency of step a) and said schizophrenia-negative frequency of step b) to determine statistically whether said association between said allele and schizophrenia exists.